Viaskin Peanut: A Promising Non-Invasive Solution for Children’s Peanut Allergies with Strong Market Potential
PremiumRatingsViaskin Peanut: A Promising Non-Invasive Solution for Children’s Peanut Allergies with Strong Market Potential
1M ago
DBV Technologies announces three-year results from EPITOPE trial
Premium
The Fly
DBV Technologies announces three-year results from EPITOPE trial
3M ago
DBV Technologies announces FDA alignment on Viaskin Peanut patch program pathway
Premium
The Fly
DBV Technologies announces FDA alignment on Viaskin Peanut patch program pathway
4M ago
DBV Technologies announces ADS ratio change
PremiumThe FlyDBV Technologies announces ADS ratio change
5M ago
0QAJ Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
0QAJ Earnings this Week: How Will it Perform?
5M ago
DBV Technologies rating suspended at Goldman Sachs
Premium
The Fly
DBV Technologies rating suspended at Goldman Sachs
5M ago
DBV Technologies completes patient screening for VITESSE trial
PremiumThe FlyDBV Technologies completes patient screening for VITESSE trial
7M ago
DBV Technologies price target raised to $5 from $4 at JMP Securities
Premium
The Fly
DBV Technologies price target raised to $5 from $4 at JMP Securities
8M ago
DBV Technologies reports Q2 EPS (34c), consensus (45c)
Premium
The Fly
DBV Technologies reports Q2 EPS (34c), consensus (45c)
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100